- Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped over 50%.
- Mizuho thinks that investors need to make a clear distinction as they reassess their position after these inconclusive results and no-sample-size adjustment communication.
- Is there any new risk with the actual science and data itself? Mizuho writes:
- The interim data was based mainly on the Phase 1 data, which showed that six-month EDSS improvement was >85% predicative of that at 12 months. But the study itself was small, with only 24 patients.
- Data was even smaller, with EDSS data on 34 patients at six months and 15 patients at twelve months.
- The analyst notes dose and time-dependent response from the single-arm ATA188 Phase 1, sustained disability EDSS improvement in the 33-50% range in the higher dose cohorts, and similar data from autologous sister compound ATA190.
- Mizuho keeps the price target at $39 with a Buy rating.
- Price Action: ATRA shares are down 55% at $3.90 during the market session on the last check Wednesday.
What Will Drive Columbia Care’s Future Growth? Analyst Opines Post Positive Q3 Earnings
Columbia Care Inc. (NEO: CCHW) (OTC: CCHWF) (FSE: 3LP) reported its financial results Friday for the third quarter ended September 30, revealing record quarterly revenue of $132.3 million, up by 144% year-over-year and 21% sequentially.
